2022
DOI: 10.1016/j.jff.2022.105024
|View full text |Cite|
|
Sign up to set email alerts
|

Brusatol inhibits the invasion and migration of pancreatic cancer cells by suppressing the NRF2/NF-κB/STAT3 signal cascade

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 31 publications
0
3
0
Order By: Relevance
“…Terpenoid molecules have been proposed as effective NRF2 inhibitors and potential chemotherapeutics. This was recently confirmed by Xiang et al for brusatol [ 137 ], a triterpenoid lactone, which proved to be an effective inhibitor of cell invasion and migration via NRF2 pathway. For another bioactive diterpenoid, oridonine, the inhibitory effect of its terpenoid moiety on the NRF2 pathway was confirmed in human osteosarcoma cells, associated with the promotion of apoptotic effect, in vitro and in vivo [ 138 ].…”
Section: Plant Bioactive Compounds—alkaloids As Nrf2 Inhibitorsmentioning
confidence: 55%
“…Terpenoid molecules have been proposed as effective NRF2 inhibitors and potential chemotherapeutics. This was recently confirmed by Xiang et al for brusatol [ 137 ], a triterpenoid lactone, which proved to be an effective inhibitor of cell invasion and migration via NRF2 pathway. For another bioactive diterpenoid, oridonine, the inhibitory effect of its terpenoid moiety on the NRF2 pathway was confirmed in human osteosarcoma cells, associated with the promotion of apoptotic effect, in vitro and in vivo [ 138 ].…”
Section: Plant Bioactive Compounds—alkaloids As Nrf2 Inhibitorsmentioning
confidence: 55%
“…Brusatol (BRU), a quassinoid, isolated from Brucea javanica, has been identified as a potent inhibitor of the Nrf2 signaling pathway [27,28]. In recent years, much evidence has demonstrated that BRU has good anti-tumor activity in different cancers, such as colorectal [29], liver [30,31], lung [32], and pancreatic cancer [33], as well as BC [34]. For example, Lu et al reported that BRU could effectively inhibit the cell viability of colorectal cancer cells HCT116 [35].…”
Section: Introductionmentioning
confidence: 99%
“…Recently, Chen et al demonstrated that the synergistic effect of BRU with cisplatin could enhance the antitumor effect on colorectal cancer cells [45]. Xiang et al found that BRU enhanced the anti-tumor effect of gemcitabine by inhibiting the Nrf2 signaling pathway in pancreatic cancer cells [33]. In addition to combination therapy strategies for PD, Zhang et al first showed that combining PD with an inhibitory glycolytic compound, 2-Deoxy-d-glucose (2-DG), inhibited proliferation, migration and invasion and induced apoptosis in MCF7 and 4T1 cells [38].…”
Section: Introductionmentioning
confidence: 99%